SCHEMBL6091944

SCHEMBL6091944

N[C@@H]1CCN2c3c(cccc31)C(=O)N[C@H]2c1cccnc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
KDM4E B2RXH2 7/20 0.38
GLA P06280 2/20 0.38
HPGD P15428 2/20 0.38
GAA P10253 1/20 0.38
CHRNB2 P17787 4/20 0.36
CHRNA4 P43681 4/20 0.36
CHRNA7 P36544 3/20 0.36
CHRNB4 P30926 2/20 0.36
CHRNA3 P32297 2/20 0.36
CHRNA2 Q15822 2/20 0.36
CYP2A6 P11509 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
PSIP1 O75475 1/20 0.36
TRPA1 O75762 1/20 0.36
HTR3B O95264 1/20 0.36
CHRNA1 P02708 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092751 1.00 ALDH1A1 (0.38) ALDH1A1KDM4EGLAHPGDGAA
SCHEMBL6090730 0.86 TNKS2 (0.35) ALDH1A1KDM4ELMNAHTR3AHSD17B10
SCHEMBL6089791 0.86 TNKS2 (0.35) ALDH1A1KDM4ELMNAHTR3AHSD17B10
SCHEMBL6091992 0.82 PARP1 (0.35) ALDH1A1KDM4EHSD17B10
SCHEMBL6090413 0.82 PARP1 (0.35) ALDH1A1KDM4EHSD17B10
SCHEMBL6089696 0.82 TNKS2 (0.39) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL6090392 0.82 TNKS2 (0.39) ALDH1A1KDM4EHPGDGAANPSR1
SCHEMBL6089150 0.81 MEN1 (0.39) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL6092215 0.81 MEN1 (0.39) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL6092437 0.81 ALDH1A1 (0.45) ALDH1A1KDM4EGAAMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 ALDH1A1 1890/4885KDM4E 812/4885GLA 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.